Michael Liebman

Michael N. Liebman received the B.S. degree from Drexel University, Philadelphia, PA, in 1970, and the Ph.D. degree from Michigan State University, Lansing, in 1977, both in physical chemistry. He is currently Executive Director of the Windber Research Institute, Windber, PA, after serving as Chief Scientific Officer since November 2003. Prior to this, he was Director of Computational Biology and Biomedical Informatics at the Abramson Family Cancer Research Institute of the University of Pennsylvania Cancer Center. He previously was Global Head of Computational Genomics at Roche Pharmaceuticals and Director of Bioinformatics and Pharmacogenomics at Wyeth Pharmaceuticals, Director of Genomics for Vysis, Inc, and Director of Bioinformatics at the Amoco Technology Company. His research focuses on computational models of disease progression stressing risk detection, disease process modeling, and analysis of lifestyle interactions. Dr. Liebman serves on 12 international scientific advisory boards, consults for five pharma/biotech companies, and has been on the economic development programs in the Philadelphia Life Sciences Sector and the State of Illinois Biotechnology Commission. He is a reviewer for a number of journals, including the Journal of Medicinal Chemistry, Biochimica Biophysica Acta, Journal of the American Chemical Society, and the Proceedings of the National Academy of Sciences.